



Docket No.: 114 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bell et al.

Application No: 10/771,551

Filing Date: February 3, 2004

For: Method of Treating Hemolytic Disease

CERTIFICATE OF MAILING

Date of Deposit: October 27, 2004

I hereby certify that the following:

- This Certificate of Mailing
- Request for Corrected Filing Receipt
- Filing Receipt with correction indicated in red
- Return Postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Rebecca Layman

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410



IFW
Docket No.114 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bell et al

Serial No: 10/771,551

Filed: February 03, 2004

Examiner: Unassigned

Group Art Unit: 1614

For: **Method of Treating Hemolytic Disease**

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Applicant respectfully requests that a corrected Filing Receipt be issued for this application accurately reflecting the second inventor's name to read as follows:

Russell P. Rother

Enclosed is a copy of the Filing Receipt with the requested correction indicated in red.

Kindly charge any fee associated with this request to Deposit Account No. 01-0483. TWO (2)

DUPLICATE COPIES OF THIS SHEET ARE ENCLOSED.

Respectfully submitted,



Mark Farber
Reg. No. 34,159
Attorney for Applicant

Dated: 10/27/2004

Mark Farber
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
(203) 271-8319




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 Washington, D.C. 20591-9000
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (C) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/771,552	02/03/2004	1614	2282	114 US		10	171

Mark Farber
 Alexion Pharmaceuticals, Inc.
 352 Knotter Drive
 Cheshire, CT 06410



CONFIRMATION NO. 6183
 UPDATED FILING RECEIPT



OC000000013571077

Date Mailed: 08/18/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Leonard Bell, Woodbridge, CT;
 Russell P. Rother, Prospect, CT;

Russell

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted: 05/04/2004

Projected Publication Date: 08/04/2005

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ****

Title

Method of treating hemolytic disease

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).